© 2006 The Royal College of Psychiatrists
Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia
Department of Psychiatry,Woodhull Medical and Mental Health Center, Brooklyn, New York, USA
Correspondence: Dr Robertt E. McCue, Department of Psychiatry, Wooodhull Medical and Mental Health Center, 760 Broadway, Brooklyn, New York 11206,USA. Email: mccuer{at}nychhc.org
See editorial, pp.
391–392, this
issue.
Background There is little information on the comparative effectiveness of second-generation antipsychotic agents.
Aims To determine if any of five second-generation antipsychotics or haloperidolis more effective in treating acutely ill patients with schizophrenia, schizoaffective disorder or schizophreniform disorder.
Method A sample of 327 newly admitted patients were randomised to open-label treatment with aripiprazole, haloperidol, olanzapine, quetiapine, risperidone or ziprasidone for a minimum of 3 weeks. Measures of effectiveness were improvement in mental status so that the patient no longer required acute in-patient care, and changes in Brief Psychiatric Rating Scale (BPRS) scores.
Results By the first measure, haloperidol (89%), olanzapine (92%) and risperidone (88%) were significantly more effective than aripiprazole (64%), quetiapine (64%) and ziprasidone (64%). Changes in BPRS ratings were not significant among treatments.
Conclusions Haloperidol, olanzapine and risperidone are superior to aripiprazole, quetiapine and ziprasidone for the acute treatment of psychosis in hospitalised patients with schizophrenia, schizoaffective disorder or schizophreniform disorder.
Related articles in BJP:
- The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries
- CLIVE E. ADAMS, PRATHAP THARYAN, EVANDRO S. F. COUTINHO, and T. SCOTT STROUP
BJP 2006 189: 391-392.[Abstract] [Full Text] - PETER TYRER
BJP 2006 189: 478.[Full Text]
This article has been cited by other articles:
 |
|
 |
|
  J.-C. SHIM and D. L. KELLY Drs. Shim and Kelly Reply Am J Psychiatry, March 1, 2008; 165(3): 397 - 398. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Millan, C. M. la Cour, F. Novi, R. Maggio, V. Audinot, A. Newman-Tancredi, D. Cussac, V. Pasteau, J.-A. Boutin, T. Dubuffet, et al. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], A Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: I. Receptor-Binding Profile and Functional Actions at G-Protein-Coupled Receptors J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 587 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Taylor Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia Evid. Based Ment. Health, August 1, 2007; 10(3): 76 - 76. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hodgson, C. Bushe, and R. Hunter Measurement of long-term outcomes in observational and randomised controlled trials The British Journal of Psychiatry, August 1, 2007; 191(50): s78 - s84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lepping Antipsychotics preferred by mental health professionals Psychiatr. Bull., July 1, 2007; 31(7): 272 - 272. [Full Text] [PDF]
|
|
|
|
|
|
R. E McCue Clozapine improves symptoms but not quality of life compared with other second-generation antipsychotics in people with treatment resistant schizophrenia Evid. Based Ment. Health, May 1, 2007; 10(2): 57 - 57. [Full Text] [PDF]
|
|
eLetters:
Read all eLetters
- A flawed design
- Taiwo A Ajayi
- BJP Online, 3 Nov 2006 [Full text]